Join our daily newsletter At The Bell to receive exclusive market insights
- Noxopharm Limited (NOX) announces a shift in leadership in preparation for an upcoming ‘growth phase’
- Dr Gisela Mautner has been appointed as CEO starting next month, with former CEO Dr Graham Kelly remaining on the board
- Dr Mautner joined Noxopharm three years ago and oversaw the implementation of the company’s clinical programs
- Dr Kelly will remain actively involved in Noxopharm’s future given his previous impact on the company
- Noxopharm’s share price was up 4.9 percent to trade at 43 cents at midday AEDT
Noxopharm Limited (NOX) announces a shift in leadership in preparation for an upcoming ‘growth phase’.
Dr Gisela Mautner has been appointed as CEO starting next month, with former CEO Dr Graham Kelly remaining on the board, shifting from an executive to a consulting role.
Dr Mautner, currently the Chief Medical Officer, will earn $410,000pa and will also serve as Executive Managing Director on the board.
“I feel very honoured to be chosen as its next CEO and I am excited to lead the company through its next stages,” she said.
“I look forward to working with the board and the talented team at Noxopharm to deliver success and value for our many stakeholders.”
Dr Mautner is a medical doctor with pharmaceutical industry experience covering all aspects from clinical research to product commercialisation.
In her early career, Dr Mautner worked as a clinical scientist at the National Institutes of Health in the USA.
Dr Mautner has a master’s degree in public health from Harvard University and an MBA from Northwestern University, Kellogg School of Management and has served on the executive committee of the Australian Pharmaceutical Medical and Scientific Professionals Association (APPA).
Dr Mautner joined Noxopharm three years ago and oversaw the implementation of the company’s clinical programs.
Dr Kelly said the company is in the process of transiting from an early-stage biotech company into a serious bio-pharma company looking to make its mark on the world stage.
“As the company’s largest shareholder, ongoing board member and inventor of much of the company’s intellectual property, I intend to remain actively involved in the company’s future,” he said.
Noxopharm shares were in the green by 4.9 percent at 43 cents at midday AEDT.
